Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Study of LY2541546 vs Placebo in Postmenopausal Women with Low Bone Mineral Density
jRCT2080221242Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of blosozumab in low bone mineral density, osteopenia and osteoporosis (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in lumbar spine bone mineral density. Started Sep 2010; status: completed.
02
Drugs
blosozumab
03
Conditions
low bone mineral densityosteopeniaosteoporosis
Beyond the preview
Go deeper on jRCT2080221242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221242.